(S)-1-Boc-3-Hydroxypiperidine CAS 143900-44-1 Ibrutinib Intermediate Purity >99.0% (GC)

Short Description:

Chemical Name: (S)-1-Boc-3-Hydroxypiperidine

CAS: 143900-44-1

Chiral Purity: >99.0% (GC)

Chemical Purity: >99.0% (GC)

Appearance: White Powder or Crystals

Intermediate of Ibrutinib (CAS: 936563-96-1)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Chemical Properties:

Chemical Name	(S)-1-Boc-3-Hydroxypiperidine
Synonyms	(S)-1-(tert-Butoxycarbonyl)-3-Hydroxypiperidine; (S)-1-Boc-3-Piperidinol
CAS Number	143900-44-1
CAT Number	RF-CC299
Stock Status	In Stock, Production Capacity 20 Tons/Month
Molecular Formula	C10H19NO3
Molecular Weight	201.27
Melting Point	52.0~56.0℃
Solubility	Soluble in Methanol
Specific Rotation [a]20/D	+9.0°~+11.0° (C=1 in Chloroform)
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White Powder or Crystals
Chiral Purity	>99.5% (GC)
Chemical Purity	>99.5% (GC)
Water (K.F)	≤0.50%
Methanol (GC)	≤50ppm
Ethanol (GC)	≤50ppm
DCM (GC)	≤500ppm
3-Hydroxypiperidine	≤0.10%
3-Hydroxypyridine	≤0.20%
1-Boc-3-Piperidone	≤0.10%
1-Boc-4-Hydroxypiperidine	≤0.10%
1.96 RRT	≤0.20%
Any Unspecified Impurity	≤0.10%
Test Standard	Enterprise Standard
Usage	Pharmaceutical Intermediates; Chiral Compounds

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

FAQ:

Application:

(S)-1-Boc-3-Hydroxypiperidine (CAS: 143900-44-1) is an important chiral intermediate for the synthesis of Ibrutinib (CAS: 936563-96-1). Ibrutinib is a kind of Bruton tyrosine kinase (BTK) inhibitor, it could be used for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). MCL and CLL are belonged to the B-cell non-Hodgkin's lymphoma, which is difficult to cure and easy to recurrent. Common chemical immunotherapy does not have the targeting, often occurs 3 or 4 adverse reactions. Ibrutinib and B lymphocytes could target with BTK which is necessary for formation, differentiation, and transmission of information, inhibit BTK activity irreversibly, and inhibit tumor cell proliferation and survival effectively. Ibrutinib could be rapidly absorbed after oral administration, during 1~2h reach maximum blood concentration, adverse reactions belong to one or two, therefore, Ibrutinib will become a new choice of treatment of CLL and MCL.